We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+18.29%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$250M
AUM Growth
-$27.1M
Cap. Flow
-$42M
Cap. Flow %
-16.77%
Top 10 Hldgs %
58.37%
Holding
52
New
6
Increased
8
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
ALGS icon
Aligos Therapeutics
ALGS
+$5.46M
2
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$5.2M
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$4.88M
4
GHRS icon
GH Research
GHRS
+$3.06M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$2.84M

Top Sells

Rank Stock Value
1
ETNB
89bio
ETNB
+$9.32M
2
CRIS icon
Curis
CRIS
+$8.69M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$7.11M
4
MRSN
Mersana Therapeutics
MRSN
+$5.79M
5
ALT icon
Altimmune
ALT
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 87.44%
2 Financials 5.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.04B
$3.33M 1.33%
369,863
-11,282
-3% -$108K
GHRS icon
27
GH Research
GHRS
$1.93B
$3.26M 1.3%
+150,000
New +$3.06M
ACRS icon
28
Aclaris Therapeutics
ACRS
$772M
$3.07M 1.23%
175,000
-142,730
-45% -$3.24M
GYRE icon
29
Gyre Therapeutics
GYRE
$681M
$2.97M 1.19%
91,333
-33,934
-27% -$1.16M
SAGE
30
DELISTED
Sage Therapeutics
SAGE
$2.89M 1.16%
50,945
-67,555
-57% -$4.78M
RAIN
31
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$2.52M 1.01%
+162,245
New +$2.84M
ATXS
32
DELISTED
Astria Therapeutics
ATXS
$2.48M 0.99%
+195,612
New +$2.54M
CPRX
33
DELISTED
Catalyst Pharmaceutical
CPRX
$1.89M 0.76%
329,134
+251,134
+322% +$1.3M
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$1.48M 0.59%
60,000
-22,000
-27% -$512K
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.42M 0.57%
10,000
-4,000
-29% -$452K
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$1.32M 0.53%
301,904
-13,437
-4% -$59.6K
NVAX icon
37
Novavax
NVAX
$1.22B
$491K 0.2%
2,315
-821
-26% -$150K
NUVB.WS
38
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$236K 0.09%
90,832
-2,500
-3% -$8.15K
ALT icon
39
Altimmune
ALT
$583M
– –
-407,055
Closed -$5.75M
CMPS
40
Compass Pathways
CMPS
$1.52B
– –
-90,000
Closed -$3.31M
CRIS icon
41
Curis
CRIS
$10M
– –
-1,919
Closed -$8.69M
ETNB
42
DELISTED
89bio
ETNB
– –
-393,548
Closed -$9.32M
FDMT icon
43
4D Molecular Therapeutics
FDMT
$527M
– –
-20,000
Closed -$868K
INSM icon
44
Insmed
INSM
$21.3B
– –
-42,500
Closed -$1.45M
MRSN
45
DELISTED
Mersana Therapeutics
MRSN
– –
-14,308
Closed -$5.79M
PMVP icon
46
PMV Pharmaceuticals
PMVP
$59.7M
– –
-13,856
Closed -$456K
PRAX icon
47
Praxis Precision Medicines
PRAX
$8.52B
– –
-10,282
Closed -$5.05M
RAPT
48
DELISTED
RAPT Therapeutics
RAPT
– –
-25,036
Closed -$4.45M
STOK icon
49
Stoke Therapeutics
STOK
$1.84B
– –
-45,000
Closed -$1.75M
MRTX
50
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-9,000
Closed -$1.54M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Acuta Capital Partners held 52 positions worth $250M, down 9.8% from $277M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Acuta Capital Partners withdrew a net $42M in Q2 2021, closing 14 positions and reducing 20 holdings. Its most notable exit was 89bio, an estimated $9.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 91% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Aligos Therapeutics worth $4.37M.

  • Acuta Capital Partners's largest Q2 2021 buy was Aligos Therapeutics: 8,570 shares worth $4.37M.
  • Acuta Capital Partners added most to Seelos Therapeutics, Inc. Common Stock in Q2 2021, an estimated $4.88M increase.
  • Acuta Capital Partners's biggest Q2 2021 reduction was Sage Therapeutics, cutting an estimated $4.78M.
  • Acuta Capital Partners fully exited 89bio in Q2 2021, selling an estimated $9.32M.
  • Acuta Capital Partners's ten largest holdings make up 58% of its $250M portfolio in Q2 2021.
  • Acuta Capital Partners opened 6 new positions and closed 14 in Q2 2021.
  • Acuta Capital Partners's portfolio value fell 9.8% quarter-over-quarter to $250M.

Based on Acuta Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.